Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Stuttgart,,Germany,-,10-03-2022:,Mobile,Phone,With,Logo,Of,American

News

Downgrades

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AXTA

COTY

MCRB

TOVX

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Uber,Sign,On,Its,Headquarters,Building,In,San,Francisco,,California,

COHR

HLLY

KRRO

PAYC

SONO

UBER

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Alhambra,,Ca,,Usa,-,May,11,,2022:,Quest,Diagnostics,Logo

Intraday Update

Movers

BTDR

BULL

CALX

CIFR

CVNA

FSLR

HSAI

RIOT

SEDG

Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday

Seres Therapeutics Inc

Press Releases

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Financing

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Health Care

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Earnings

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

General

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Cibus

Coherus Oncology

Climb Bio

Elutia

EXoZymes

Forte Biosciences

Immunic

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Macrogenics

MediciNova

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Pyxis Oncology

Quince Therapeutics

Surrozen

TScan Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Chardan Capital

Goldman Sachs

Canaccord Genuity

Oppenheimer

HC Wainwright & Co.

Comments

Seres Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell